Literature DB >> 19786839

Is new always better than old?: The development of human vaccines for anthrax.

Leslie W Baillie1.   

Abstract

Anthrax is caused by a Gram-positive aerobic spore-forming bacillus called Bacillus anthracis. Although primarily a disease of animals, it can also infect man, sometimes with fatal consequences. As a result of concerns over the illicit use of this organism, considerable effort is focused on the development of therapies capable of conferring protection against anthrax. while effective concerns over the toxicity of the current vaccines have driven the development of second-generation products. Recombinant Protective Antigen (rPA), the nontoxic cell-binding component of anthrax lethal toxin, is the principal immunogen of the vaccines currently undergoing human clinical trials. While these new vaccines are likely to show reduced side effects they will still require multiple needle based dosing and the inclusion of the adjuvant alum which will make them expensive to administer and stockpile. To address these issues, researchers are seeking to develop vaccine formulations capable of stimulating rapid protection following needle-free injection which are stable at room temperature to facilitate stockpiling and mass vaccination programs. Recent concerns over the potential use of molecular biology to engineer vaccine resistant strains has prompted investigators to identify additional vaccine targets with which to extend the spectrum of protection conferred by rPA. While the injection of research dollars has seen a dramatic expansion of the anthrax vaccine field it is sobering to remember that work to develop the current second generation vaccines began around the time of the first gulf war. Almost two decades and millions of dollars later we still do not have a replacement vaccine and even when we do some argue that the spectrum of protection that it confers will not be as broad as the vaccine it replaces. If we are to respond effectively to emerging biological threats we need to develop processes that generate protective vaccines in a meaningful time frame and yield products in months not decades!

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786839     DOI: 10.4161/hv.9777

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  16 in total

1.  Mechanistic Analysis of the Effect of Deamidation on the Immunogenicity of Anthrax Protective Antigen.

Authors:  Anita Verma; Miriam M Ngundi; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2016-05-06

2.  Optic Atrophy Secondary to Preseptal Cutaneous Anthrax: Case Report.

Authors:  Metin Ekinci; H Hüseyin Çağatay; Nergiz Hüseyinoğlu; Erdinç Ceylan; Gökçen Gökçe
Journal:  Neuroophthalmology       Date:  2014-07-22

3.  Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Authors:  Leslie Wagner; Anita Verma; Bruce D Meade; Karine Reiter; David L Narum; Rebecca A Brady; Stephen F Little; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-07-18

Review 4.  New developments in vaccines, inhibitors of anthrax toxins, and antibiotic therapeutics for Bacillus anthracis.

Authors:  J M Beierlein; A C Anderson
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.

Authors:  Karina Ramirez; Yanina Ditamo; James E Galen; Les W J Baillie; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

6.  The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax.

Authors:  Karen E Brenneman; Mehmet Doganay; Arya Akmal; Stanley Goldman; Darrell R Galloway; Alfred J Mateczun; Alan S Cross; Leslie W Baillie
Journal:  FEMS Immunol Med Microbiol       Date:  2011-04-15

7.  An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Authors:  Les W Baillie; Theresa B Huwar; Stephen Moore; Gabriela Mellado-Sanchez; Liliana Rodriguez; Brendan N Neeson; Helen C Flick-Smith; Dominic C Jenner; Helen S Atkins; Rebecca J Ingram; Danny M Altmann; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-08-04       Impact factor: 3.641

8.  An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.

Authors:  Jianfeng Zhang; Edward Jex; Tsungwei Feng; Gloria S Sivko; Leslie W Baillie; Stanley Goldman; Kent R Van Kampen; De-chu C Tang
Journal:  Clin Vaccine Immunol       Date:  2012-10-24

9.  Use of site-directed mutagenesis to model the effects of spontaneous deamidation on the immunogenicity of Bacillus anthracis protective antigen.

Authors:  Anita Verma; Beth McNichol; Rocío I Domínguez-Castillo; Juan C Amador-Molina; Juan L Arciniega; Karine Reiter; Bruce D Meade; Miriam M Ngundi; Scott Stibitz; Drusilla L Burns
Journal:  Infect Immun       Date:  2012-10-31       Impact factor: 3.441

10.  A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.

Authors:  Manish Manish; Amit Rahi; Manpreet Kaur; Rakesh Bhatnagar; Samer Singh
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.